EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2023
TABLES
226
PAGES
423
EDITION
8
PRICE
USD 5450
CODE
MCP16869
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Tuberculosis Testing Market to Reach $2.6 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Tuberculosis Testing estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$2.6 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Culture-Based Tests, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$634.3 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chest X-Ray segment is readjusted to a revised 3.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $117.7 Million, While China is Forecast to Grow at 5.4% CAGR
The Tuberculosis Testing market in the U.S. is estimated at US$117.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$330.1 Million by the year 2027 trailing a CAGR of 5.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.1% and 3.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.1 Billion by the year 2027.
Interferon-Gamma Release Assay (IGRA) Segment to Record 6.5% CAGR
In the global Interferon-Gamma Release Assay (IGRA) segment, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$47.8 Million in the year 2020 will reach a projected size of US$69.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 6.2% CAGR through the analysis period.
SELECT PLAYERS
Abbott Laboratories, Inc.; Akonni Biosystems, Inc.; Becton, Dickinson and Company; bioMérieux SA; Cepheid, Inc.; Creative Diagnostics; F. Hoffmann-La Roche AG; Hain Lifescience GmbH.; Hologic, Inc.; LIONEX Diagnostics & Therapeutics GmbH; Oxford Immunotec Ltd.; QIAGEN; Sanofi SA; Thermo Fisher Scientific Inc.
SEGMENTS
» Test Type (Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests, Other Test Types) » End-Use (Hospitals, Physicians Office, Reference Laboratories, Other End-Uses)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Impact of Covid-19 and a Looming Global Recession |
Year 2021 in Review and Near-term Outlook |
EXHIBIT: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023 |
COVID-19 Unravels Progress against Tuberculosis & Pushes Mortality for First Time in Decade |
Exhibit: Tuberculosis, a Disease that Wont Quit: Global Prevalence of Tuberculosis (In 000s) by Geographic Region for the Year 2022 |
Exhibit: Tuberculosis Prevalence Rate Remains High Among Asian Americans: % TB Prevalence in the United States by Race/Ethnicity as of the Year 2022 |
Exhibit: Tuberculosis Prevalence Rate In (%) in the United States by Origin of Birth as of the Year 2022 |
Exhibit: The US Makes Steady Progress Towards TB Elimination: Number of TB Cases for Years 1985, 1995, 2005, 2015, 2020 and 2022 |
Low Funding Remains Palpable Challenge |
Table: Funding for Tuberculosis is Vital for Reaching the Elimination Threshold Which is Defined as 1 Case Per 1,000,000 People: U.S. Funding for Tuberculosis (In US$ Million) for Years 2001, 2005, 2009, 2013, 2017, 2021, 2023 |
Surge in Tuberculosis Deaths amid COVID-19: A Wake-Up Call to Drive R&D Funding |
Efforts to Integrate Testing for TB & COVID-19 |
World Market Trajectories |
Tuberculosis Testing – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2022 (E) |
Global Market Overview and Outlook |
Global Tuberculosis Testing Market Exuding High Degree of Vim & Vigor |
North America Claims Commanding Revenue Share |
Culture-based Tests & Hospitals: Primary Contributors to Tuberculosis Testing Market |
Salient Factors Influencing Dynamism of Global Tuberculosis Testing Market |
Intense Competition Drive Players to Bet on Innovations |
Molecular Diagnosis Innovations Soaking Up Limelight in the Tuberculosis Testing Arena |
W.H.O Aims to Improve Access to Rapid Molecular Tests for Diagnosis of TB & Drug-Resistant TB |
WHO-Endorsed Molecular Platforms & Tests |
Recent Market Activity |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Global Tuberculosis Efforts to Drive the Market for Tuberculosis Testing |
Bracing Technological Innovations, Tuberculosis Testing Moves in New Direction |
Tuberculosis Screening: The Dawn of Artificial Intelligence Technology |
Nanodiagnostics Set to Witness Growth in TB Testing |
A Nanobiosensor for Rapid Detection of Mycobacterium Tuberculosis |
CRISPR-based Biosensing to See Significant Growth in Pediatric Tuberculosis |
Present Limitations and Future Directions |
4. GLOBAL MARKET PERSPECTIVE |
World Tuberculosis Testing Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027 |
World Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Culture-Based Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Chest X-Ray by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Interferon-Gamma Release Assay (IGRA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Mantoux Test (TST) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Smear Microscopy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Nucleic Acid Testing (NAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Serological Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Physicians Office by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
USA Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
USA Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
CANADA |
Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
JAPAN |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
CHINA |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
China Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
China Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
China Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
EUROPE |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
FRANCE |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
France Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
France Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
France Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
GERMANY |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
ITALY |
Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
UNITED KINGDOM |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
UK Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
UK Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Spain Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Spain 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Russia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Russia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
ASIA-PACIFIC |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
AUSTRALIA |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Australia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Australia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
INDIA |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
India Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
India Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
India Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
India 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
South Korea Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
South Korea 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
LATIN AMERICA |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Latin America 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Argentina Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Argentina 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Brazil Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Brazil 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Mexico Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Mexico 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Latin America 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
MIDDLE EAST |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Middle East 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
IRAN |
Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Iran Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Iran 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Israel Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Israel 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Saudi Arabia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Saudi Arabia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
UAE Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
UAE 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Rest of Middle East 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
AFRICA |
Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2012, 2021 & 2027 |
Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Africa Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR |
Africa 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2012, 2021 & 2027 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com